Author: Valenzuela-Almada, MarÃa O.; Putman, Michael S.; Duarte-GarcÃa, AlÃ
Title: The Protective Effect of Rheumatic Disease Agents in COVID-19 Cord-id: 0dax3h7f Document date: 2021_1_13
ID: 0dax3h7f
Snippet: Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical Coronavirus Disease 2019. Notable examples include corticosteroids, interleukin 6, interleukin 1, Janus kinase, and tumor necrosis alpha inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be
Document: Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical Coronavirus Disease 2019. Notable examples include corticosteroids, interleukin 6, interleukin 1, Janus kinase, and tumor necrosis alpha inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials are ongoing to determine the role of other immunosuppressants.
Search related documents:
Co phrase search for related documents- activator janus kinase signal transducer and lung damage: 1
- activator janus kinase signal transducer and lung disease: 1
- activator janus kinase signal transducer and macrophage activation: 1
- activator janus kinase signal transducer and macrophage activation syndrome: 1
- active phase and acute ards respiratory distress syndrome: 1
- active phase and lung damage: 1, 2, 3, 4
- active phase and lung disease: 1, 2
- active phase and macrophage activation: 1
- active phase and macrophage activation syndrome: 1
- active trial and adaptive phase: 1
- active trial and lung disease: 1
- acute ards respiratory distress syndrome and adaptive phase: 1, 2
- acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
- acute ards respiratory distress syndrome and long term effect: 1
- acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute ards respiratory distress syndrome and lung dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute ards respiratory distress syndrome and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date